Keyphrases
5-fluorouracil (5-FU)
14%
5-year Survival
20%
Adjuvant Chemotherapy
6%
After Surgery
8%
Arteriovenous Malformation
28%
Brain Arteriovenous Malformation (bAVM)
19%
Brain Metastases
32%
Carcinoembryonic Antigen
20%
Carcinoembryonic Antigen Levels
13%
Carcinoma
12%
Cerebral Arteriovenous Malformation
15%
Chemotherapy
19%
Clinical Outcomes
11%
Clinical Papers
12%
Clinical Significance
13%
Colon Cancer
18%
Colon Cancer Cells
9%
Colorectal Cancer
100%
Colorectal Cancer Cells
11%
Colorectal Cancer Patients
43%
Colorectal Carcinoma
7%
Completely Resected
11%
Confidence Interval
16%
Curative Resection
14%
Curative Surgery
21%
Digital Subtraction Angiography
7%
Disease-free Survival
17%
Distant Metastasis
11%
Dural Arteriovenous Fistula (dAVF)
11%
Embolization
7%
FOLFOX
6%
Gamma Knife Radiosurgery
49%
Gastrectomy
7%
Gastric Adenocarcinoma
11%
Gastric Cancer
50%
Gastric Cancer Patients
27%
Gastric Carcinoma
11%
General Hospital
18%
Genetic Modification
11%
Hazard Ratio
14%
High Risk
10%
Hypermethylation
6%
Independent Prognostic Factor
14%
International multicenter Study
20%
Intracranial Dural Arteriovenous Fistula
7%
Leucovorin
9%
Liver Metastasis
10%
Local Recurrence
6%
Local Tumor Control
7%
Lung Adenocarcinoma
11%
Lymph Node Metastasis
20%
Lymphovascular Invasion
9%
Magnetic Resonance Imaging
13%
Meningioma
8%
Metastasis
10%
Metastatic Colorectal Cancer (mCRC)
34%
Microsatellite Instability-high (MSI-H)
22%
Mortality Rate
7%
Multi-institutional Study
8%
Multivariate Analysis
23%
National Cohort Study
12%
Non-small Cell Lung Cancer (NSCLC)
16%
Obliteration
13%
Odds Ratio
7%
Overall Survival
42%
Overall Survival Rate
7%
Overexpression
19%
Oxaliplatin
8%
Patient Survival
9%
Patients with Colorectal Cancer
15%
Polymorphism
7%
Poor Prognosis
13%
Post-recurrence Survival
6%
Prognostic Factors
27%
Prognostic Indicator
8%
Prognostic Significance
9%
Prognostic Value
12%
Progression-free Survival
8%
Radiosurgery
31%
Resection
17%
Right-sided Colon Cancer
8%
Risk Factors
14%
Stereotactic Radiosurgery
93%
Stomach
10%
Surgical Outcomes
12%
Surgical Resection
9%
Survival Rate
8%
Taipei
20%
Taiwan
36%
Taiwanese
7%
Treatment Outcome
8%
Tumor
55%
Tumor Cells
9%
Tumor Control
9%
Tumor Recurrence
10%
Tumor Size
12%
Tumor Volume
11%
Univariate Analysis
9%
Vestibular Schwannoma
11%
Young Patients
7%
Medicine and Dentistry
Abdominal Cancer
65%
Adenocarcinoma
8%
Adjuvant Chemotherapy
5%
Anastomosis Leakage
5%
Apoplexy
5%
Arteriovenous Malformation
30%
Biological Marker
6%
Bleeding
25%
Brain Metastasis
28%
Breast Cancer
11%
Cancer
10%
Cancer Cell
11%
Cancer Growth
5%
Cancer Surgery
5%
Carcinoembryonic Antigen
19%
Carcinogenesis
7%
Carcinoma
11%
Cavernous Sinus
7%
Cerebral Arteriovenous Malformation
19%
Chemoradiotherapy
9%
Cohort Analysis
21%
Colon
6%
Colon Carcinoma
25%
Colorectal Carcinoma
87%
Colorectal Surgery
6%
Comorbidity
5%
Digital Subtraction Angiography
5%
Disease Free Survival
16%
Diseases
31%
Distant Metastasis
8%
Dural Arteriovenous Fistula
15%
Embolization
8%
Epidermal Growth Factor Receptor
6%
Fasciocutaneous Flap
5%
Fistula
5%
Fluorouracil
5%
Free Tissue Graft
9%
Gamma Knife Radiosurgery
24%
Gastrectomy
23%
Gene Mutation
11%
Hazard Ratio
11%
In Vitro
7%
Laparoscopic Surgery
10%
Liver Metastasis
11%
Lung Adenocarcinoma
12%
Lung Cancer
16%
Lymph Node
15%
Lymph Node Metastasis
23%
Lymphovascular Invasion
8%
Magnetic Resonance Imaging
9%
Malignant Neoplasm
18%
Meningioma
9%
Metastasectomy
8%
Metastatic Carcinoma
29%
Metastatic Colorectal Cancer
7%
Microsatellite Instability
9%
Mortality Rate
7%
Multivariate Analysis
16%
Neoplasm
95%
Non Small Cell Lung Cancer
14%
Odds Ratio
6%
Operation Duration
5%
Overall Survival
46%
Pediatrics
5%
Pneumonectomy
6%
Primary Tumor
7%
Prognostic Factor
34%
Progression Free Survival
7%
Proportional Hazards Model
10%
Quality of Life
6%
Radiation Necrosis
5%
Radiation Response
5%
Radiation Therapy
8%
Radiosurgery
28%
Randomized Controlled Trial
6%
Rectum Cancer
23%
Recurrent Disease
40%
Retroperitoneal Lymph Node Dissection
7%
Retrospective Cohort Study
6%
Retrospective Study
11%
Squamous Cell Carcinoma
5%
Stereotactic Radiosurgery
84%
Stomach Adenocarcinoma
8%
Stomach Carcinoma
8%
Surgeon
5%
Surgery
53%
Survival Rate
22%
Total Mesorectal Excision
5%
Tumor Cell
6%
Tumor Progression
6%
Tumor Recurrence
7%
Univariate Analysis
7%
Vestibular Schwannoma
5%